A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Trial Profile

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Durvalumab (Primary) ; Epacadostat (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ECHO-203
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
    • 02 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2018.
    • 30 Oct 2014 Incyte Corporation has entered into a clinical trial agreement with AstraZeneca to conduct this trial, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top